Skip to content

Advertisement

AIDS Research and Therapy

What do you think about BMC? Take part in

Featured collection: HIV vaccine development in Canada

Prompted by the Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office (ACO) meeting in 2016, this collection highlights the contribution of Canadian scientists to the goal of developing an effective HIV vaccine. 

The authors in this issue provide outstanding and clear opinions/reviews on key topics related to understanding the underlying factors for vaccine design, vaccine delivery strategies, adjuvants, and other prevention measures, as well as therapeutic vaccines.

Articles

  1. Content type: Research

      |  

    Authors: María Fernanda Álvarez Barreneche, Carlos Andrés Restrepo Castro, Alicia Hidrón Botero, Juan Pablo Villa Franco, Ivan Mauricio Trompa Romero, Laura Restrepo Carvajal, Alejandro Eusse García, Adriana Ocampo Mesa, Lina María Echeverri Toro, Glenys Patricia Porras Fernández de Castro, Jaime Mauricio Ramírez Rivera and Carlos Andrés Agudelo Restrepo

View all articles
View all articles

Editors-in-Chief

Eric Arts, Western University, Canada

Mark Boyd, University of Adelaide, Australia

Aims and scope

AIDS Research and Therapy  publishes articles on basic science, translational, clinical, social, epidemiological, behavioral  and educational sciences articles focused on the treatment and prevention of HIV/AIDS, and the search for the cure.  The Journal publishes articles on novel and developing treatment strategies for AIDS as well as on the outcomes of established treatment strategies. Original research articles on animal models that form an essential part of the AIDS treatment research are also considered

Featured review: The therapeutic landscape of HIV-1 via genome editing

This review highlights some of the mechanisms underlying the application of genome editing as a major control to augment existing strategies against HIV-1 infection. Fighting HIV-1 cannot be achieved using a single therapeutic strategy but by a combinational approach of existing and new strategies yet to be developed.  It is imperative for intensive and collaborative research across various biomedical disciplines to develop better strategies for optimization of these tools while opening up new avenues for the treatment of HIV-1.

E Arts

Dr Eric Arts

Eric J Arts is Chair of the Department of Microbiology and Immunology at Western University in London, Canada. His research for the past 16 years described in over 120 publications has focused on HIV-1 fitness, evolution, and virulence in regards to transmission, disease progression, immune escape, drug resistance, and global HIV spread.

Since 1998, he has directed the research laboratories at the Joint Clinical Research Centre, Kampala, Uganda and has collaborated with investigators in Zimbabwe, China, Cameroon, Belgium, UK, France, Brazil, and Argentina. His research has been supported by grants from the NIH (NIAID, NICHD, and NHLBI), from the State of Ohio, Merck, and amfAR. He has served as chair and member of the NIH and CIHR grant panel and has reviewed grants for the many governments around the world.

Dr Mark Boyd

Dr Mark Boyd

Dr Mark Boyd is Professor and Chair of Medicine at the University of Adelaide based at the Lyell McEwin Hospital. He is the current President of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM).

Dr Boyd has published the SECOND-LINE and Encore1 studies, the results of which have been incorporated into the most recent (2016) WHO integrated guidelines for the management of HIV-infection.

In 2014, Dr Boyd was awarded the prestigious Frank Fenner Prize for Advanced Research in Infectious Diseases by the Australasian Society for Infectious Diseases (ASID). Dr Boyd has attracted over 20 million AUD in research funding from government, industry and non-government organisational sources. He collaborates with colleagues in HIV clinical research worldwide, particularly in the Asia-Pacific region.

Advertisement